Phase 2 Trials
LSD Therapy
LSD (lysergic acid diethylamide) is being researched for anxiety disorders and generalized anxiety. Definium Therapeutics (formerly MindMed) is leading Phase 2 trials with their MM-120 formulation.
50Clinical Trials
1Companies
0Legal States
FDA StatusPhase 2 Trials
Legal PathwayFDA approval pathway (federal)
Also Known Aslysergic acid diethylamide, acid, MM120
Legal Status by State
View full legal tracker →Fully Operational
Legal, Launching
Decriminalized
Active Legislation
Research Only
No Activity
Clinical Trials
11 trials currently recruiting
Phase 121
Phase 213
Phase 36
Active, Not Recruiting·Phase 3·LSD
A Phase 3 Trial of MM120 for Major Depressive Disorder (Emerge)
Definium Therapeutics US, Inc.
Major Depressive Disorder
Active, Not Recruiting·Early Phase 1·LSD
LSD Occupancy of the Serotonin 2A Receptor in the Human Brain
Rigshospitalet, Denmark
Basic Science
Approved for Marketing·N/A·LSD
BMN 110 US Expanded Access Program
BioMarin Pharmaceutical
Mucopolysaccharidosis IVAMorquio A SyndromeMPS IVA
Completed·N/A·LSD
Salivary Oxytocin as a Biomarker in Psychedelic Assisted Psychotherapy
Tatiana Aboulafia Brakha
Depression, Anxiety
Completed·N/A·LSD
LSD-Perceptual-Choice-Study
University Hospital, Basel, Switzerland
LSD Reaction
Completed·Phase 1·LSD
Effect of Ketanserin, Olanzapine, and Lorazepam After LSD Administration on the Acute Response to LSD in Healthy Subjects
University Hospital, Basel, Switzerland
Healthy
Companies & Research
Organizations developing LSD-based therapies